AMRX

SEC source: 0001628280-25-010693 · wk-form4_1741221213.xml · derivative · entry 6

Patel Chirag K. · CIK 0001738701 · Director · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 579,710 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2.

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2.

F1 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2.

SEC source: 0001628280-25-010693 · wk-form4_1741221213.xml · nonDerivative · entry 2

Patel Chirag K. · CIK 0001738701 · Director · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 812,749

F2 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

SEC source: 0001628280-25-010693 · wk-form4_1741221213.xml · nonDerivative · entry 1

Patel Chirag K. · CIK 0001738701 · Director · President & Co-CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,092,276

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2.

SEC source: 0001628280-25-010679 · wk-form4_1741219921.xml · nonDerivative · entry 1

Patel Gautam · CIK 0001738054 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,808,886

F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15,2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.73 to $8.98 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 13

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,178

Underlying: Class A Common Stock · 94,178 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F10 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026.

F10 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 12

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,356

Underlying: Class A Common Stock · 188,356 shares

Expires not disclosed

F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 94,178 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units will be deemed earned and vested when settled into shares of Class A Common Stock shortly after February 28, 2028, the last day of the performance period.

F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 94,178 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units will be deemed earned and vested when settled into shares of Class A Common Stock shortly after February 28, 2028, the last day of the performance period.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 11

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 144,928 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 10

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,743

Underlying: Class A Common Stock · 45,872 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · derivative · entry 9

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,232

Underlying: Class A Common Stock · 36,232 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 6

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420,543

F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 5

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 494,674

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 4

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,746

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 3

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 373,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 2

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,338

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-25-010678 · wk-form4_1741219884.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-25-010118 · wk-form4_1741133025.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 31,371 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-25-010118 · wk-form4_1741133025.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,304

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-25-010118 · wk-form4_1741133025.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,041

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-25-010115 · wk-form4_1741132756.xml · derivative · entry 3

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 36,197 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001628280-25-010115 · wk-form4_1741132756.xml · nonDerivative · entry 2

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 550,019

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-25-010115 · wk-form4_1741132756.xml · nonDerivative · entry 1

Konidaris Tasos · CIK 0001320982 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 563,513

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-25-010113 · wk-form4_1741132675.xml · derivative · entry 3

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 28,958 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal payments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 115,830 restricted stock units, vesting in four equal payments beginning on the first anniversary of the grant date.

SEC source: 0001628280-25-010113 · wk-form4_1741132675.xml · nonDerivative · entry 2

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 309,639

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001628280-25-010113 · wk-form4_1741132675.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,624

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-25-004064 · wk-form4_1738791099.xml · nonDerivative · entry 1

Patel Gautam · CIK 0001738054 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,888,886

F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.02 to $8.28 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001628280-25-001153 · wk-form4_1736544318.xml · nonDerivative · entry 1

Patel Gautam · CIK 0001738054 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,968,886

F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.04 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001628280-25-000581 · wk-form4_1736198539.xml · nonDerivative · entry 1

Patel Gautam · CIK 0001738054 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,031,476

F1 · price: These transactions occurred automatically pursuant to a plan adopted by the Reports Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-049149 · wk-form4_1732569962.xml · nonDerivative · entry 2

Autor Deborah M. · CIK 0001884671 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,402

F2 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 per share to $8.41 per share, inclusive. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-049297 · wk-form4_1732657281.xml · derivative · entry 3

Kiely John · CIK 0001781149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 28,506 shares

Expires 2029-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is vested and currently exercisable.

SEC source: 0001628280-24-049297 · wk-form4_1732657281.xml · nonDerivative · entry 2

Kiely John · CIK 0001781149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,175

F1 · shares: Reflects shares sold to cover the exercise price arising in connection with the exercise of the stock options.

SEC source: 0001628280-24-049297 · wk-form4_1732657281.xml · nonDerivative · entry 1

Kiely John · CIK 0001781149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 284,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-049005 · wk-form4_1732311507.xml · nonDerivative · entry 1

Daly Jason B. · CIK 0001906486 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001628280-24-049149 · wk-form4_1732569962.xml · nonDerivative · entry 1

Autor Deborah M. · CIK 0001884671 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,631

F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.38 to $8.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

SEC source: 0001628280-24-048437 · wk-form4_1732051018.xml · nonDerivative · entry 1

Daly Jason B. · CIK 0001906486 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,665

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $9.00 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-037559 · wk-form4_1723839496.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,670

F2 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 per share to $7.92 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-037559 · wk-form4_1723839496.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,895

F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 per share to $7.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-037557 · wk-form4_1723839453.xml · nonDerivative · entry 1

Shah Nikita · CIK 0001738061 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,666

F1 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $7.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-024342 · wk-form4_1716235819.xml · nonDerivative · entry 2

Autor Deborah M. · CIK 0001884671 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,402

F1 · shares: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.

F3 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.77 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-024342 · wk-form4_1716235819.xml · nonDerivative · entry 1

Autor Deborah M. · CIK 0001884671 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,849

F1 · shares: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.79 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-24-023256 · wk-form4_1715719430.xml · derivative · entry 2

MEISTER PAUL M · CIK 0001033876 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 107,034 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 107,034 restricted stock units vesting on May 10, 2024.

F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 107,034 restricted stock units vesting on May 10, 2024.

SEC source: 0001628280-24-023256 · wk-form4_1715719430.xml · nonDerivative · entry 1

MEISTER PAUL M · CIK 0001033876 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 727,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-24-023258 · wk-form4_1715719474.xml · derivative · entry 2

Autor Deborah M. · CIK 0001884671 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 76,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

SEC source: 0001628280-24-023258 · wk-form4_1715719474.xml · nonDerivative · entry 1

Autor Deborah M. · CIK 0001884671 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,402

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-24-023248 · wk-form4_1715719307.xml · derivative · entry 2

George Jeffrey P. · CIK 0001796789 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 76,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

SEC source: 0001628280-24-023248 · wk-form4_1715719307.xml · nonDerivative · entry 1

George Jeffrey P. · CIK 0001796789 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-24-023252 · wk-form4_1715719371.xml · derivative · entry 2

Kiely John · CIK 0001781149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 76,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

F2 · derivative.expiration_date: On May 9, 2023 the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

SEC source: 0001628280-24-023252 · wk-form4_1715719371.xml · nonDerivative · entry 1

Kiely John · CIK 0001781149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-24-023262 · wk-form4_1715719548.xml · derivative · entry 2

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 76,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

F2 · derivative.expiration_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

SEC source: 0001628280-24-023262 · wk-form4_1715719548.xml · nonDerivative · entry 1

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001628280-24-023247 · wk-form4_1715719263.xml · derivative · entry 2

BUCHI J KEVIN · CIK 0001209726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 76,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.

F2 · derivative.expiration_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024.